Aeterna Zentaris

About Aeterna Zentaris

Aeterna Zentaris (NASDAQ:AEZS) is a biopharmaceutical company focused on developing and commercializing novel treatments in oncology, endocrinology and women's health. With a pipeline of innovative therapies aimed at addressing unmet medical needs, the company's research and development strategy prioritizes the advancement of its lead candidates. Aeterna Zentaris is dedicated to improving patient outcomes and enhancing quality of life through groundbreaking scientific research. Its objective is to become a key player in the biopharmaceutical field by delivering effective solutions for conditions with significant treatment gaps.

What is Aeterna Zentaris known for?

Snapshot

1990

Year founded

Employees

South Carolina, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Aeterna Zentaris

Macimorelin, an orally active ghrelin agonist for diagnosing adult growth hormone deficiency.
Development of a potential treatment for Myasthenia Gravis, leveraging their expertise in autoimmune diseases.
A portfolio of novel oncology compounds targeting innovative therapeutic approaches for cancer.
Research into potential treatments for pediatric growth hormone deficiency, expanding the application of macimorelin.
Partnerships for the development and commercialization of diagnostic and therapeutic products worldwide.
Advancements in peptide receptor radionuclide therapy (PRRT) for the treatment of certain tumors.